




Supplemental Table I

<u>Treatment</u>	<u>Strain</u>	<u>pre-treatment weight (g)</u>	<u>pre-treatment SBP (mmHg)</u>	<u>pre-treatment DBP (mmHg)</u>	<u>pre-harvest weight (g)</u>	<u>treatment SBP (mmHg)</u>	<u>treatment DBP (mmHg)</u>	<u>serum aldosterone (nM)</u>
vehicle + control IgG	C57Bl/6	24.0 0.5	111.0 1.3	81.1 1.1	26.0 0.5	106.0 2.8	76.5	1.6 0.20
aldosterone + control IgG	C57Bl/6	25.0 0.5	109.0 4.2	82.0 2.8	25.3 0.6	115.4 5.0	78.1 4.7	9.8 2.3*
vehicle + VEGFR1 ab	C57Bl/6	23.7 0.3	97.9 3.8	71.4 3.4	25.1 0.3	101.2 4.6	71.9 4.28	1.2 0.07
aldosterone + VEGFR1 ab	C57Bl/6	24.0 0.3	103.5 1.3	74.1 1.9	25.9 0.5	102.5 2.6	74.4 2.5	7.9 1.8*
vehicle + VEGFR2 ab	C57Bl/6	25.7 0.7	113.3 1.6	77.43 2.5	26.2 0.7	111.8 7.9	87.0 9.6	1.9 0.51
aldosterone + VEGFR2 ab	C57Bl/6	27.2 0.6	88.9 3.1	62.8 3.0	27.8 0.6	109.7 3.5	88.4 5.1	8.4 2.1*

Supplemental Table I: Increased serum aldosterone levels in aldosterone-infused mice treated with control IgG, VEGFR1-blocking antibody (ab), or VEGFR2-blocking ab with no change in blood pressure or animal weight. SBP=systolic blood pressure, DBP=diastolic blood pressure. * = P<0.05 vs vehicle.

Supplemental Figure I



Supplemental Figure I: Role of PIGF and VEGFR1 in aldosterone-enhanced carotid SMC proliferation *in vitro*.

(A) Primary mouse carotid SMC were treated *in vitro* with aldosterone (Aldo) at the indicated concentration and the percent increase in SMC proliferation compared to vehicle-treated cells was quantified after two days. N=6-7 experiments. *P<0.01 versus 0 nM Aldo. **(B)** Mouse carotid SMC treated with vehicle, Aldo (10nM), or Aldo + eplerenone (EPL, 1µM) for 8 hours. PIGF and VEGFR1 mRNA expression were quantified by QRT-PCR. N=5-8 experiments. *P<0.05 versus vehicle. **(C)** Mouse carotid SMC treated with Aldo (10nM) or vehicle (Veh) in the presence of control IgG, VEGFR1- or VEGFR2-blocking antibodies (ab) for 2 days. Bars represent the average percent increase in SMC proliferation compared to Veh with control IgG treatment. N=8 experiments. * P<0.05 versus all Veh-treated, # P<0.05 versus Aldo-treated with IgG.